H Lundbeck A/S (LUN)

158.7
-3.3(-2.07%)
  • Volume:
    376,310
  • Bid/Ask:
    0.0/0.0
  • Day's Range:
    157.8 - 162.7
  • Type:Equity
  • Market:Denmark
  • ISIN:DK0010287234
  • S/N:199148222

LUN Overview

Prev. Close
162
Day's Range
157.8-162.7
Revenue
16.52B
Open
162.5
52 wk Range
157.8-260.4
EPS
8.54
Volume
376,310
Market Cap
31.53B
Dividend (Yield)
2.50
(1.54%)
Average Vol. (3m)
348,287
P/E Ratio
18.98
Beta
1.28
1-Year Change
-14.06%
Shares Outstanding
198,698,326
Next Earnings Date
Feb 09, 2022
What is your sentiment on H Lundbeck A/S?
or
Market is currently closed. Voting is open during market hours.

H Lundbeck A/S Company Profile

Employees
5588
Market
Denmark

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company’s principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer’s disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington’s disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • got something of this pharma in my portfolio...lon g term investment. Specyfical sector (neuroligal, brain, mood) very strategic in my opinion.
    0
    • JPMorgan 250 kr 12/5-21
      0
      • Åi6
        0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.